Lenco Laboratory Update:
New Test – PULS Test

Lenco Laboratory is pleased to announce we now offer PULS (Protein Unstable Lesion Signature) Cardiac Test™. This test measures the body’s immune response to endothelial damage to predict Acute Coronary Syndrome (ACS).

The PULS Cardiac Test measures key clinical risk factors including age, sex, diabetic status, and family history of heart attack as well as distinct protein biomarkers (IL-16, MCP-3, Eotaxin, CTACK, Fas, Fas Ligand, HGF, HDL, HbA1C). These markers are the body’s immune response associated with the biological pathways underlying cardiac lesion formation, progression and rupture. This refined methodology of cardiac risk assessment provides an improved calculation of a patient’s near-term (5 year) risk for a heart attack.

CLINICAL SIGNIFICANCE

- Cardiovascular risk prediction models such as the Framingham Risk Score calculate risk of a cardiovascular event within the next 10 years. When used, these calculations rely heavily on established clinical risk factors¹ which do not fully estimate the prevalence of cardiovascular disease in the general population.²,³
The PULS Cardiac Test™ measures clinically significant protein immune responses in the blood associated with active unstable cardiac lesion formation, and key clinical risk factors to predict whether a cardiac lesion could rupture within a 5 year period.  

If you have any questions, please call your Lenco Sales/Service Representative or our Client Services Department at 718-232-1515, ext 9.

Best Regards,

Dr. Elena Agranovsky
Medical Director

REFERENCES